At Johnson & Johnsonwe believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented treated and curedwhere treatments are smarter and less invasive andsolutions are our expertise in Innovative Medicine and MedTech we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for more at .

As guided by Our Credo Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson we respect the diversity and dignity of our employees and recognize their merit.

Job Function:

Job Sub Function:

Job Category:

All Job Posting Locations:

Job Description:

Job Title: Solid Tumor China NPP Lead/Associate Strategic Marketing Director

Reporting Line

Reports to: APSO Solid Tumor TA Lead
Matrix collaboration with: APSO OpCo Solid Tumors teams China R&D (CCT) Medical Market Access BD and Commercial Operations

Purpose of the Role

The China Solid Tumors Strategic Marketing New Product Planning Lead is accountable for shaping and driving the longterm pipeline and portfolio strategy for Solid Tumour oncology in China from early clinical stages through prelaunch readiness.

This role serves as the strategic bridge between global asset development and Chinas unique market needs ensuring future assets indications and business models are fitforChina competitively differentiated and launchready. The role leads China NPP strategy across key solid tumour disease areas and plays a critical role in influencing global development priorities lifecycle strategy and portfolio investment decisions.

Key Responsibilities

1. China Solid Tumours Pipeline & Portfolio Strategy

• Own and drive the China Solid Tumours NPP strategy spanning early to latestage assets and indications.

• Define Chinaspecific strategic imperatives disease area priorities and portfolio sequencing aligned to unmet medical need and commercial opportunity.

• Lead pipeline sufficiency and portfolio gap analysis versus current and future competitive landscapes in China.

• Develop and articulate clear China value narratives for pipeline assets to support governance prioritization and investment decisions.

2. Early Asset & Indication Shaping

• Influence Target Product Profiles (TPPs) indication sequencing and clinical development strategies to optimize China relevance.

• Partner closely with China Compound Team (CCT) APSO DAS lead and Medical Affairs to ensure early integration of commercial insights.

• Provide strategic input at key global development milestones (preIND Phase IIII lifecycle extensions).

• Identify Chinaspecific opportunities including biomarkers precision medicine strategies combination approaches and novel access models.

3. PreLaunch & Launch Excellence Readiness

• Lead China prelaunch strategic planning for priority solid tumour assets ensuring seamless transition from NPP to inline teams.

• Define future launch archetypes success metrics and critical enablers (diagnostics patient pathways ecosystem readiness).

• Ensure early alignment across Commercial Medical Market Access and Operations on launch ambition and execution model.

4. CrossFunctional & Global Leadership

• Act as the China strategic interface to global and regional Solid Tumours teams.

• Lead and influence complex matrixed crossfunctional teams without direct authority.

• Partner with Business Development to assess external opportunities collaborations and pipeline expansion options relevant to China.

• Represent China perspectives in global governance forums ensuring Chinas voice is clearly articulated and influential.

5. Strategic Planning & Governance

• Drive China Solid Tumours longrange strategic planning (LRFP BP) from a pipeline and portfolio perspective.

• Support senior leadership with highquality strategic insights scenario planning and decision frameworks.

• Ensure all activities are compliant with internal governance ethics and regulatory requirements.

Key Stakeholders

• AP Solid Tumours DAS & Asset Teams

• China Oncology Leadership Team

• China R&D / CCT

• Medical Affairs Market Access Commercial Excellence

• Business Development & Strategic Insights

Qualifications & Experience

Required

• Bachelors degree required; MBA PhD PharmD or MD strongly preferred

• Extensive experience in oncology strategic marketing NPP portfolio strategy or commercial strategy

• Strong understanding of China oncology market dynamics including policy access and competitive environment

• Proven ability to influence global development and lifecycle strategy without direct reporting lines

• Experience across early and latestage pipeline assets

Preferred

• Solid tumour therapeutic area expertise (e.g. lung GU GI bladder CRC breast head & neck)

• Experience working in matrixed globalregionallocal organizations

• Exposure to precision medicine diagnostics or novel modalities

• Strong strategic storytelling and executive communication skills

Critical Capabilities

• Enterpriselevel strategic thinking

• Strong commercial and clinical acumen

• High influence and stakeholder management capability

• Comfort with ambiguity and earlystage decisionmaking

• Ability to translate complexity into clear strategic choices

Success Measures

• Strength and clarity of China Solid Tumours pipeline strategy

• Degree of China influence on global asset and indication decisions

• Quality of prelaunch readiness for priority assets

• Leadership impact across crossfunctional and global stakeholders

Required Skills:

Preferred Skills: